What is ABECMA? ABECMA (idecabtagene vicleucel) is a prescription medicine for the treatment of multiple myeloma in patients who have received at least four kinds of treatment regimens that have not worked or have stopped working. ABECMA is a medicine made from your own white blood cells; the cells are genetically modified to recognize and attack your multiple myeloma cells.
This website is best viewed using the horizontal display on your tablet device.
This website is best viewed using the vertical display on your mobile device.
ABECMA may be right for you if you have tried at least 4 kinds of treatment regimens and have received at least 1 therapy from each of these drug classes:
You may have received these treatments at the same time or one after the
other. If you do not know whether or not you have received these treatments,
please consult with your doctor.
You may be eligible for ABECMA regardless of your prior eligibility for an SCT.
In the ABECMA clinical trial, 92% of patients had previously received an SCT.
Your doctor will also assess your overall health, including your age, when
determining your eligibility for ABECMA. Adults 18 and over may be eligible for